UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate

Clinical pharmacokinetics, 2008-01, Vol.47 (5), p.285-295

Stangier, Joachim

2008

Volltextzugriff (PDF)

Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor

Clinical and applied thrombosis/hemostasis, 2009-02, Vol.15 (1_suppl), p.9S-16S

2009

Volltextzugriff (PDF)

Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran

Blood coagulation & fibrinolysis, 2012-03, Vol.23 (2), p.138-143

2012

Volltextzugriff (PDF)

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

The New England journal of medicine, 2017-08, Vol.377 (5), p.431-441

2017

Volltextzugriff (PDF)

Idarucizumab for Dabigatran Reversal

The New England journal of medicine, 2015-08, Vol.373 (6), p.511-520

2015

Volltextzugriff (PDF)

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

Thrombosis and haemostasis, 2010-06, Vol.103 (6), p.1116-1127

2010

Volltextzugriff (PDF)

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial

The Lancet (British edition), 2015-08, Vol.386 (9994), p.680-690

2015

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

Clinical pharmacokinetics, 2008, Vol.47 (1), p.47-59

2008

Volltextzugriff (PDF)

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

British journal of clinical pharmacology, 2007-09, Vol.64 (3), p.292-303

2007

Volltextzugriff (PDF)

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

Drug metabolism and disposition, 2008-02, Vol.36 (2), p.386-399

2008

Volltextzugriff (PDF)

Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin

Arteriosclerosis, thrombosis, and vascular biology, 2010-10, Vol.30 (10), p.1885-1889

2010

Volltextzugriff (PDF)

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

Thrombosis and haemostasis, 2015, Vol.114 (1), p.198-205

2015

Volltextzugriff (PDF)

Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study)

The American journal of cardiology, 2007-11, Vol.100 (9), p.1419-1426

2007

Volltextzugriff (PDF)

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

The American journal of medicine, 2016-11, Vol.129 (11), p.S64-S72

2016

Volltextzugriff (PDF)

Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

Journal of the American College of Cardiology, 2016-04, Vol.67 (13), p.1654-1656

2016

Volltextzugriff (PDF)

Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement

Journal of clinical pharmacology, 2005-05, Vol.45 (5), p.555-565

2005

Volltextzugriff (PDF)

Idarucizumab, A specific reversal agent for dabigatran: Mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects

The American journal of emergency medicine, 2016-11, Vol.34 (11), p.26-32

2016

Volltextzugriff (PDF)

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies

British journal of clinical pharmacology, 2017-08, Vol.83 (8), p.1815-1825

2017

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate

Thrombosis and haemostasis, 2012-02, Vol.107 (2), p.260-269

2012

Volltextzugriff (PDF)

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

The New England journal of medicine, 2017-08, Vol.377 (5), p.431-441

2017

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis of the New Oral Thrombin Inhibitor Dabigatran Etexilate (BIBR 1048) in Patients Undergoing Primary Elective Total Hip Replacement Surgery

Journal of clinical pharmacology, 2007-03, Vol.47 (3), p.371-382

2007

Volltextzugriff (PDF)

Abstract 18403: Effect of Dabigatran on the Ability to Generate Fibrin at a Wound site and its Reversal by Idarucizumab, the Antidote to Dabigatran, in Healthy Volunteers: An Exploratory Marker of Blood Loss

Circulation (New York, N.Y.), 2014-11, Vol.130 (suppl_2)

2014

Volltextzugriff (PDF)

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate: An Open-Label, Parallel-Group, Single-Centre Study

Clinical pharmacokinetics, 2010-04, Vol.49 (4), p.259-268

2010

Volltextzugriff (PDF)

Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study

Research and practice in thrombosis and haemostasis, 2017-10, Vol.1 (2), p.202-215

2017

Volltextzugriff (PDF)

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran

Thrombosis and haemostasis, 2015-05, Vol.113 (5), p.943-951

2015

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(84)

Sprache

Englisch
(84)
Japanisch
(25)

Erscheinungsjahr

n.n

Thema

Science & Technology
(60)
Life Sciences & Biomedicine
(59)
Humans
(49)
Male
(36)
Pharmacology & Pharmacy
(31)
Biological And Medical Sciences
(29)
Middle Aged
(29)
Dabigatran
(27)
Adult
(26)
Female
(26)
Medical Sciences
(24)
Benzimidazoles - Pharmacokinetics
(23)
Pharmacology. Drug Treatments
(19)
Benzimidazoles - Administration & Dosage
(17)
Cardiovascular System & Cardiology
(17)
Aged
(16)
Administration, Oral
(15)
Benzimidazoles - Adverse Effects
(15)
Benzimidazoles - Pharmacology
(15)
Pyridines - Pharmacokinetics
(15)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate

Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor

Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Idarucizumab for Dabigatran Reversal

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial

Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study)

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement

Idarucizumab, A specific reversal agent for dabigatran: Mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies

Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Population Pharmacokinetic Analysis of the New Oral Thrombin Inhibitor Dabigatran Etexilate (BIBR 1048) in Patients Undergoing Primary Elective Total Hip Replacement Surgery

Abstract 18403: Effect of Dabigatran on the Ability to Generate Fibrin at a Wound site and its Reversal by Idarucizumab, the Antidote to Dabigatran, in Healthy Volunteers: An Exploratory Marker of Blood Loss

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate: An Open-Label, Parallel-Group, Single-Centre Study

Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran

Suchergebnisse filtern